WGU D345 Pre- Assessment (Latest 2026/ 2027 Update) Psychopharmacology for Advanced Psychiatric Mental Health Practice| 100% Verified Questions & Answers | Grade A

WGU D345 Pre- Assessment (Latest 2026/ 2027 Update) Psychopharmacology for Advanced Psychiatric Mental Health Practice| 100% Verified Questions & Answers | Grade A Q: A combat veteran presents with anxiety, flashbacks, distressing dreams, irritable mood, and sleep disturbance. The patient's capacity for enjoyment is limited and the patient avoids people and places that trigger memories of combat due to anxiety and feeling uncomfortable. Which medication should be used to treat this patient? a. Olanzapine (Zyprexa) b. Selegiline (Emsam) c. Quetiapine (Seroquel) d. Sertraline (Zoloft) ANS: D Sertraline (Zoloft) is the appropriate medication for this patient, who presents with symptoms consistent with post-traumatic stress disorder (PTSD). Selective serotonin reuptake inhibitors (SSRIs) such as sertraline are first-line pharmacologic treatments for PTSD due to their efficacy in reducing anxiety, intrusive thoughts, and hyperarousal symptoms. Atypical antipsychotics like olanzapine and quetiapine may be used as adjunctive treatments but are not first-line. Selegiline is a monoamine oxidase inhibitor (MAOI) primarily used for Parkinson's disease and depression, not PTSD. Thus, sertraline is the best option for treating PTSD symptoms in this combat veteran. Q: A nurse practitioner (NP) completes an assessment for the presence of abnormal involuntary movements on a patient who has been taking various psychotropic medications for the past several years. The NP diagnoses the patient with tardive dyskinesia (TD).Which medication should be prescribed to treat the patient? a. Duloxetine (Cymbalta) b. Phenelzine (Nardil) c. Propranolol (Inderal) d. Deutetrabenazine (Austedo) ANS: D Deutetrabenazine (Austedo) is the appropriate medication for treating tardive dyskinesia (TD). TD is a movement disorder characterized by repetitive, involuntary movements, often caused by long-term use of dopamine-blocking agents such as antipsychotics. Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor, which helps reduce dopamine release and mitigate abnormal involuntary movements. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for depression and chronic pain conditions. Phenelzine is a monoamine oxidase inhibitor (MAOI) used for treatment-resistant depression, not TD. Propranolol is a beta-blocker used primarily for essential tremors and akathisia but is not effective for TD. Thus, deutetrabenazine is the best choice for treating TD in this patient. Q: A patient with a history of social anxiety and no previous medication history recently started college. Upon moving into the dormitories, the patient immediately experienced heightened anxiety and reported low moods. Which medication should be used to address these symptoms? a. Olanzapine (Zyprexa) b. Risperidone (Risperdal) c. Paroxetine (Paxil) d. Aripiprazole (Abilify) ANS: C Paroxetine (Paxil) is the appropriate medication for this patient, who presents with symptoms consistent with social anxiety disorder (SAD) and possibly comorbid depressive symptoms. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine are the first-line pharmacologic treatment for social anxiety disorder due to their efficacy in reducing excessive fear, anxiety, and avoidance behaviors in social situations. Olanzapine, risperidone, and aripiprazole are atypical antipsychotics, which are not first-line treatments for social anxiety disorder. While they may be used adjunctively in treatment resistant cases or for comorbid conditions such as schizophrenia or bipolar disorder, they are not the primary choice for this patient's presentation. Thus, paroxetine is the best choice to treat social anxiety and low mood in this college student. Q: A seven-year-old child is referred to the school psychologist for ongoing disturbances in the classroom. The child struggles with inattention, restlessness, impulsivity, and excessive talking. After multiple sessions with the child, the school psychologist decides to refer the child to a local nurse practitioner (NP) based on a diagnosis of attention deficit hyperactivity disorder (ADHD). Which medication should this NP prescribe? a. Amphetamine (Adzenys ER) b. Quetiapine (Seroquel) c. Olanzapine (Zyprexa) d. Cariprazine (Vraylar) ANS: A Amphetamine (Adzenys ER) is the appropriate medication for this child, who presents with symptoms consistent with attention deficit hyperactivity disorder (ADHD). Stimulant medications, such as amphetamines and methylphenidate, are first-line treatments for ADHD and are highly effective in improving attention, reducing impulsivity, and managing hyperactivity. Quetiapine, olanzapine, and cariprazine are atypical antipsychotics, which are not first-line treatments for ADHD. These medications are typically used for conditions such as schizophrenia or bipolar disorder and are not recommended for managing ADHD symptoms in children. Thus, amphetamine (Adzenys ER) is the best choice for treating this child's ADHD symptoms. Q: A school-age child diagnosed with separation anxiety disorder and treated with psychotherapy continues to exhibit symptoms. The child has not been able to attend kindergarten. Which medication should be used to treat this disorder? a. Citalopram (Celexa) b. Clonidine (Catapres) c. Aripiprazole (Abilify) d. Amitriptyline (Elavil) ANS: A Citalopram (Celexa) is the appropriate medication for this child, who presents with separation anxiety disorder (SAD) that has not responded to psychotherapy alone. Selective serotonin reuptake inhibitors (SSRIs), such as citalopram, are the first-line pharmacologic treatment for pediatric anxiety disorders, including separation anxiety. SSRIs help reduce excessive fear, distress, and avoidance behaviors, enabling the child to better cope with being apart from caregivers. Clonidine is an alpha-2 adrenergic agonist primarily used for ADHD-related hyperactivity and impulsivity, not separation anxiety. Aripiprazole is an atypical antipsychotic used for conditions like autism-related irritability, bipolar disorder, and schizophrenia, not first-line for anxiety disorders. Amitriptyline is a tricyclic antidepressant (TCA) that is not commonly used in children due to its side effect profile and risk of toxicity. Thus, citalopram is the best choice for treating separation anxiety disorder in this child. Q: A nurse practitioner (NP) has a patient who is taking lamotrigine (Lamictal) for bipolar maintenance. The patient is well maintained on the medication. The patient expresses a desire to start oral contraceptives. Which psychoeducation should the NP provide to the patient in response to this request? a. It is okay for the patient to start the oral contraceptive if the patient remains in contact with the NP. b. Some oral contraceptives may increase lamotrigine levels, so the dosage may need to be decreased. c. Lamotrigine is contraindicated, so it needs to be cross-titrated to another mood stabilizer. d. Some oral contraceptives may decrease lamotrigine levels, so the dose may need to be increased. ANS: D Some oral contraceptives may decrease lamotrigine levels, so the dose may need to be increased. Estrogen-containing oral contraceptives can induce the metabolism of lamotrigine by increasing the activity of glucuronidation, leading to reduced lamotrigine plasma concentrations and potentially decreased efficacy in mood stabilization. This interaction may necessitate a dose adjustment of lamotrigine to maintain therapeutic levels. Lamotrigine is not contraindicated with oral contraceptives, so cross-titration to another mood stabilizer is not necessary. Additionally, the interaction between lamotrigine and oral contraceptives is well-documented, meaning proactive monitoring and dose adjustments are preferred over merely maintaining contact without changes. Thus, the best psychoeducation for the patient is that some oral contraceptives may decrease lamotrigine levels, requiring a dosage increase. Q: A nurse practitioner (NP) is managing a patient who has generalized anxiety disorder. Upon initial assessment, the Generalized Anxiety Disorder-7 (GAD-7) was 19. The patient was initiated on escitalopram (Lexapro) eight weeks ago and is currently taking 10 mg daily. During today's visit, the patient's GAD-7 is 15. The NP evaluates the pharmacological outcome by using standardized symptom measurements. What should the NP determine as this patient's current status and plan of treatment? a. The patient is asymptomatic, so increasing the dose is warranted. b. The patient is symptomatic, so increasing the dose is warranted. c. The patient is asymptomatic, so no change in medication is necessary. d. The patient is symptomatic, though no change in medication is necessary. ANS: B The patient is still symptomatic, so increasing the dose is warranted. The GAD-7 score has decreased from 19 to 15, indicating some improvement, but the patient still falls within the moderate to severe range of anxiety symptoms. Since the patient has been on escitalopram (Lexapro) 10 mg daily for eight weeks, an adequate trial has occurred, and further dose optimization is appropriate. The typical therapeutic dose range for escitalopram in generalized anxiety disorder (GAD) is 10 20 mg daily, meaning a dose increase to 15 or 20 mg could enhance symptom relief. Simply maintaining the current dose without further improvement would not be the best option, as the patient continues to experience distressing symptoms. Thus, the best course of action is to increase the dose of escitalopram to optimize treatment response while continuing to monitor for further symptom improvement. Q: A patient with schizophrenia, hypertension, and dyslipidemia is on the medical floor being treated for a UTI, dehydration, and a sacral pressure ulcer. They report staying in bed for over a month, not using the bathroom due to voices saying they cannot walk, and only changing a disposable brief once daily. The patient had an ED visit two months ago for hypertensive crisis after stopping antihypertensives due to hallucinations. They have been hospitalized multiple times over the past year due to medication nonadherence and resulting medical complications. How should the NP intervene? a. Appoint a medical power of attorney. b. Assess the patient's capacity for medical decision-making. c. Implement a psychiatric advanced directive. d. Assess the patient's ability to walk to the bathroom. ANS: B The appropriate intervention is to assess the patient's capacity for adequate medical decision making. This patient's history of nonadherence to antipsychotic medications, leading to repeated hospitalizations and severe medical consequences, raises concerns about impaired decision-making capacity due to schizophrenia. Their hallucinations (voices telling them they cannot walk) and delusional thinking (disregarding medical treatment advice) suggest that their ability to make informed decisions about their healthcare may be compromised. If the patient is found to lack decision-making capacity, the NP may need to involve a surrogate decision-maker or a legal guardian to ensure proper medical care. However, immediately appointing a medical power of attorney (option A) or implementing a psychiatric advanced directive (option C) without first assessing capacity would be premature. Assessing the patient's ability to ambulate (option D) is relevant but does not address the core issue of decision-making capacity that is leading to medical deterioration. Thus, the most appropriate next step is to assess the patient's capacity for adequate medical decision-making and determine the need for further psychiatric and legal interventions. Q: A high school graduate took a gap year to work with a therapist on reducing ADHD symptoms. While making significant progress, they still struggle with note-taking in science classes for their chemistry major. Diagnosed with ADHD at age six, they were previously on amphetamine (Adzenys ER) and now take the maximum dose of methylphenidate (Cotempla XR-ODT) and clonidine (Catapres) twice daily. The treatment team agrees therapy and medication have provided maximum benefit. The student has also engaged in ADHD coaching, but note-taking difficulties persist, affecting academic performance. Which action should the NP take? a. Advise the school about the diagnosis and obtain legal counsel for accommodations b. Suggest changing to an easier major and adjust medication dosages c. Suggest changing to an easier major and continue current medications d. Advise the school about the diagnosis and complete forms for accommodations ANS: D The most appropriate action is to advise the school about the diagnosis and treatment plan and complete the forms requesting accommodations. The patient has a well-established diagnosis of ADHD, has undergone comprehensive treatment with therapy, ADHD coaching, and medication at maximum benefit, yet still struggles with note-taking, which is affecting academic performance. Under the Americans with Disabilities Act (ADA) and Section 504 of the Rehabilitation Act, students with ADHD are eligible for accommodations to support their learning needs. Accommodations may include note-taking assistance, extended test-taking time, quiet testing environments, or the use of assistive technology. Changing majors is not necessary when the student has a legitimate need for support that can help them succeed in their chosen field. Seeking legal counsel is not required unless the school denies reasonable accommodations. The best intervention is to support the student in obtaining academic accommodations to improve their performance while continuing their treatment plan. Q: A patient presents to the ED with upper respiratory symptoms. History includes hypertension (controlled on lisinopril) and schizoaffective disorder (stable on clozapine). ED tests include chest X-ray, sputum culture, and CBC with differential, showing low white blood cell and neutrophil counts. The emergency physician contacts the NP for a psychiatric consult. The NP calculates absolute neutrophil count (ANC) as 1,110/µL. How should the NP manage this case? a. Stop clozapine, monitor ANC daily for one month, and coordinate care with an outpatient psychiatric prescriber. b. Stop clozapine, monitor ANC three times weekly, and coordinate care with a hematologist. c. Continue clozapine, monitor ANC daily for one month, and coordinate care with a hematologist. d. Continue clozapine, monitor ANC three times weekly until it exceeds 1,500/µL, and coordinate care with an outpatient psychiatric prescriber. ANS: D The appropriate management is to continue clozapine (Clozaril), monitor ANC three times weekly until it is greater than 1,500/µL, and coordinate care with an outpatient psychiatric prescriber. The patient's absolute neutrophil count (ANC) is 1,110/µL, which falls into the moderate neutropenia range (ANC 1,000-1,499/µL) according to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines. In cases of moderate neutropenia, clozapine can typically be continued with frequent ANC monitoring (three times weekly) until the neutrophil count recovers. Coordination with the psychiatric prescriber is essential to ensure continued treatment while balancing the risk of worsening neutropenia. Immediate discontinuation of clozapine is not necessary at this ANC level unless there is a further decline or clinical worsening. Hematology consultation is generally reserved for cases of severe neutropenia (ANC 1,000/µL). Thus, the best approach is to continue clozapine, monitor ANC three times weekly, and coordinate care with outpatient psychiatry to ensure safe continuation of treatment. Q: A 20-year-old patient arrives at a psychiatric crisis center with a friend. The patient is exhibiting symptoms of mood lability, hallucinations, and paranoia. The nurse practitioner (NP) decides to prescribe a second-generation antipsychotic medication to target the acute psychotic symptoms and arranges for inpatient admission. Which baseline lab should this NP order and continue to monitor throughout the treatment? a. Urine drug screen b. Ferritin level c. Fasting lipids d. Urinalysis ANS: C Fasting lipids should be ordered as a baseline lab and monitored throughout treatment with a second-generation antipsychotic (SGA). SGAs are associated with metabolic side effects, including dyslipidemia, weight gain, and insulin resistance, increasing the risk for cardiovascular disease. Guidelines recommend baseline and ongoing metabolic monitoring, including fasting lipids, glucose, hemoglobin A1c, and weight/BMI. A urine drug screen (UDS) is helpful in the initial evaluation to rule out substance-induced psychosis but is not required for ongoing monitoring of SGA therapy. Ferritin levels are not relevant in this context unless iron deficiency is suspected. Urinalysis may be ordered to assess for infection or medical conditions but is not a required lab for monitoring SGAs. Thus, fasting lipids should be obtained and monitored regularly to assess for metabolic complications related to SGA treatment. Q: A 32-year-old patient presents for a follow-up medication management appointment at an outpatient clinic. When asked about side effects, the patient endorses recent sexual dysfunction along with enlargement of breast tissue. A review of the medical record reveals that a second generation antipsychotic medication was started about six months ago. Lab results confirm elevated prolactin level. Which brain function is affected by a dopamine blockade to cause these side effects? a. Raphe nuclei b. Tuberoinfundibular pathway c. Nigrostriatal pathway d. Cerebral cortex ANS: B The tuberoinfundibular pathway is the brain function affected by dopamine blockade, leading to elevated prolactin levels, sexual dysfunction, and gynecomastia (enlarged breast tissue). Second generation antipsychotics (SGAs), particularly risperidone and paliperidone, can inhibit dopamine in the tuberoinfundibular pathway, which normally suppresses prolactin release. When dopamine is blocked, prolactin levels increase, resulting in hyperprolactinemia, which can cause galactorrhea, amenorrhea, sexual dysfunction, and gynecomastia. The raphe nuclei are involved in serotonin production, not prolactin regulation. The nigrostriatal pathway is associated with extrapyramidal symptoms (EPS), such as dystonia, akathisia, and tardive dyskinesia, but not prolactin-related effects. The cerebral cortex is involved in higher cognitive functions and executive control, not prolactin regulation. Thus, dopamine blockade in the tuberoinfundibular pathway is responsible for these side effects. Q: A patient is stable with minimal side effects on olanzapine (Zyprexa) for symptoms of schizophrenia. After consulting with the patient, a nurse practitioner (NP) student asks the preceptor about the dopamine theory. What should the preceptor provide as the premise of this theory? a. The N-methyl-D-aspartate receptor (NMDAR) hypofunction affects dopamine transmission. b. Hyperactivity of dopamine at D2 receptors is found in the mesolimbic pathway. c. Neurotransmitters serotonin, norepinephrine, or dopamine are depleted in the central nervous system. d. Hypoactive dopamine transmission stimulates the 5HT2A receptor hyperfunction in the cortex. ANS: B The dopamine theory of schizophrenia is based on the premise that hyperactivity of dopamine at D2 receptors in the mesolimbic pathway is associated with positive symptoms of schizophrenia, such as hallucinations, delusions, and thought disorder. This theory suggests that excess dopamine transmission in the mesolimbic pathway contributes to psychosis, while dopamine hypofunction in the mesocortical pathway may be responsible for negative symptoms and cognitive deficits. N-methyl-D-aspartate receptor (NMDAR) hypofunction (option A) is part of the glutamate hypothesis, which suggests that NMDAR dysfunction may contribute to schizophrenia. The depletion of serotonin, norepinephrine, or dopamine (option C) is more relevant to the monoamine hypothesis of depression, not schizophrenia. Hypoactive dopamine transmission stimulating 5HT2A receptor hyperfunction in the cortex (option D) is not the primary mechanism of schizophrenia, although serotonin modulation plays a role in atypical antipsychotic effects. Thus, the dopamine theory of schizophrenia is primarily centered on D2 receptor hyperactivity in the mesolimbic pathway, which explains positive symptoms and supports the mechanism of dopamine-blocking antipsychotics like olanzapine (Zyprexa). A nurse practitioner (NP) is discharging a patient on an antipsychotic medication from an inpatient setting. Which education should this NP include in the discharge teaching plan? a. Avoid excessive exposure to sunlight b. Minimize physical activity c. Rinse mouth thoroughly d. Drink lots of water to avoid constipation ANS: A Patients taking antipsychotic medications should avoid excessive exposure to sunlight due to the risk of photosensitivity and heat intolerance. Many first- and second-generation antipsychotics can cause photosensitivity reactions, increasing the risk of sunburn and skin damage. Patients should be advised to wear sunscreen, protective clothing, and sunglasses when outdoors. Minimizing physical activity (option B) is not necessary unless the patient experiences sedation or orthostatic hypotension. Rinsing the mouth (option C) is more relevant for anticholinergic side effects or dry mouth, which can occur with some antipsychotics but is not a universal precaution. Drinking water to avoid constipation (option D) is helpful, but managing hydration is more important for preventing heat intolerance caused by these medications. Thus, the most important education for discharge teaching is to avoid excessive sun exposure and take precautions against photosensitivity and heat intolerance while taking antipsychotic medications. A patient is meeting with a nurse practitioner (NP) and has some questions about a new medication, aripiprazole (Abilify). The patient understands that aripiprazole is a second generation antipsychotic. The patient wants to know what this drug blocks in the brain. Which response should this NP provide? a. Postsynaptic brain dopamine D2 receptors and serotonin receptors b. Reabsorption (reuptake) of serotonin into the neurons c. Reuptake of the neurotransmitters serotonin and norepinephrine d. Postsynaptic brain dopamine D2 receptors ANS: A Aripiprazole (Abilify) blocks postsynaptic dopamine D2 receptors and serotonin receptors while also acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors. Unlike traditional antipsychotics, which primarily block dopamine, aripiprazole's unique mechanism helps balance dopaminergic activity, reducing both positive symptoms (hallucinations, delusions) and negative symptoms (apathy, social withdrawal) of schizophrenia. Reuptake inhibition of serotonin (option B) is the mechanism of selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac). Serotonin and norepinephrine reuptake inhibition (option C) describes the mechanism of serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine (Effexor). Blocking only dopamine D2 receptors (option D) is characteristic of first-generation antipsychotics, not aripiprazole. Thus, the best response is that aripiprazole blocks postsynaptic dopamine D2 receptors and serotonin receptors while also modulating dopamine activity as a partial agonist. A 19-year-old patient is brought to an emergency department by their parents after the parents found the patient unresponsive and breathing shallowly. The parents report finding a bottle of pills next to the patient. Further investigation reveals the patient took a benzodiazepine. Which medication should be administered to this patient? a. Flumazenil (Romazicon) b. Clonazepam (Klonopin) c. Naltrexone (ReVia) d. Naloxone (Narcan) ANS: A Flumazenil (Romazicon) is the appropriate medication to administer in the case of benzodiazepine overdose. Flumazenil is a benzodiazepine receptor antagonist that rapidly reverses the sedative effects of benzodiazepines by competitively inhibiting their action at the GABA-A receptor. It is used in cases of severe respiratory depression or coma due to benzodiazepine toxicity. Clonazepam (Klonopin) is a benzodiazepine, which would worsen the overdose. Naltrexone (ReVia) is an opioid antagonist used for opioid and alcohol dependence, not benzodiazepine overdose. Naloxone (Narcan) is an opioid antagonist used for opioid overdoses, but it has no effect on benzodiazepine toxicity. Thus, flumazenil is the correct choice for reversing benzodiazepine overdose. However, it should be used cautiously, as it can precipitate seizures in patients with long-term benzodiazepine use or those at risk for withdrawal. 4o A nurse practitioner (NP) is managing a patient who has attention deficit hyperactivity disorder (ADHD), maintained with a stimulant medication. The patient comes to a session with a distinct odor of alcohol, slurred speech, and ataxia. The patient wants a refill on the stimulant. How should the NP manage this patient? a. Hold the prescription and follow up with a primary care provider b. Hold the prescription and transfer the patient to an emergency department c. Refill the prescription, with a follow-up appointment in one month d. Refill the prescription and transfer the patient to a residential addiction program ANS: A The appropriate management is to hold the prescription and follow up with a primary care provider. The patient presents with acute signs of intoxication (alcohol odor, slurred speech, ataxia), raising concerns about substance misuse or potential interactions with stimulant medication. Stimulants, such as amphetamines and methylphenidate, can increase the risk of cardiovascular issues, mood instability, and further substance misuse when combined with alcohol or other substances. Transferring the patient to an emergency department (option B) is unnecessary unless they exhibit life-threatening symptoms, such as severe respiratory depression or altered mental status. Refilling the prescription (options C and D) is inappropriate in the setting of possible active substance use. While a referral to an addiction program may be warranted in the future, it should be based on a full assessment and patient readiness for treatment rather than an immediate decision. Thus, the best approach is to hold the stimulant prescription and arrange follow-up with a primary care provider to assess for substance use concerns and overall treatment appropriateness. A patient arrives at an emergency department unconscious with a respiratory rate of four breaths per minute and miotic pupils. Which treatment should be used for this patient? a. Albuterol (Ventolin) b. Naloxone (Narcan) c. Charcoal (Actidose) d. Lorazepam (Ativan) ANS: B Naloxone (Narcan) is the appropriate treatment for this patient, who presents with opioid overdose symptoms, including unconsciousness, respiratory depression (respiratory rate of four breaths per minute), and miotic (constricted) pupils. Naloxone is an opioid antagonist that rapidly reverses the effects of opioids, restoring normal breathing and consciousness. It should be administered immediately to prevent fatal respiratory failure. Albuterol (Ventolin) is a bronchodilator used for asthma and bronchospasms but does not reverse opioid overdose. Activated charcoal (Actidose) is used for certain oral poisonings, but it is not effective for opioid overdose, particularly in an unconscious patient with respiratory depression. Lorazepam (Ativan) is a benzodiazepine, which could worsen sedation and respiratory depression in opioid toxicity. Thus, naloxone is the best choice for treating opioid overdose and should be given immediately to restore respiratory function. A patient presents with perioral dermatitis, unsteady gait, and tremor and has a strong odor of glue. The patient endorses huffing glue. Which physiological process explains these symptoms? a. Peripheral vasoconstriction b. Central nervous system depression c. Peripheral vasodilation d. Central nervous system stimulation ANS: B Central nervous system (CNS) depression explains this patient's symptoms. Inhalant abuse ("huffing glue") involves inhaling volatile substances, such as toluene, which act as CNS depressants by enhancing gamma-aminobutyric acid (GABA) activity and inhibiting glutamate. This results in drowsiness, slurred speech, ataxia (unsteady gait), and tremors. Chronic inhalant use can also lead to perioral dermatitis due to direct skin irritation from repeated exposure. Peripheral vasoconstriction (option A) is not a primary effect of inhalant use. Peripheral vasodilation (option C) may occur with some substances but is not the main physiological process causing these symptoms. CNS stimulation (option D) is associated with stimulants like cocaine and amphetamines, whereas inhalants primarily cause CNS depression. Thus, CNS depression is the primary physiological process responsible for the patient's symptoms. A 16-year-old patient is brought in by a family member after the patient ingested an unknown substance and the family member witnessed a seizure. Further assessment indicates hyperthermia, hyperreflexia, and signs of dehydration. The patient is admitted overnight for monitoring and to ensure all medical conditions are stabilized. Which substance causes these symptoms? a. 3,4-Methylenedioxymethamphetamine (MDMA) b. Delta-9-tetrahydrocannabinol (THC) c. Gamma hydroxybutyrate (GHB) d. N,N-dimethyltryptamine (DMT) ANS: A 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy" or "Molly") is the substance most likely causing these symptoms. MDMA toxicity is characterized by hyperthermia, hyperreflexia, dehydration, and seizures, which align with the patient's presentation. MDMA increases serotonin, dopamine, and norepinephrine, leading to sympathetic overactivity that can cause severe hyperthermia, rhabdomyolysis, and even serotonin syndrome in severe cases. Delta-9-tetrahydrocannabinol (THC) (option B) from cannabis does not typically cause seizures, hyperthermia, or hyperreflexia. Gamma hydroxybutyrate (GHB) (option C) is a CNS depressant that can cause sedation and respiratory depression, not hyperthermia and seizures. N,N dimethyltryptamine (DMT) (option D) is a hallucinogen that primarily causes visual distortions and altered perception, rather than the autonomic and neuromuscular effects seen in this case. Thus, the most likely substance causing these symptoms is MDMA, given its association with seizures, hyperthermia, and dehydration. An acutely manic patient is admitted to an inpatient mental health unit. A nurse practitioner (NP) diagnoses the patient with treatment-resistant bipolar disorder. Which medication should be used off-label for this patient? a. Duloxetine (Cymbalta) b. Lithium (Eskalith) c. Clozapine (Clozaril) d. Selegiline (Emsam) ANS: C Clozapine (Clozaril) is the appropriate off-label medication for treatment-resistant bipolar disorder in this acutely manic patient. While clozapine is primarily approved for treatment resistant schizophrenia, evidence supports its use in treatment-resistant bipolar disorder, particularly for severe mania, recurrent hospitalizations, and cases unresponsive to standard mood stabilizers and antipsychotics. Clozapine's unique mechanism includes dopamine D2 and serotonin 5-HT2A receptor blockade, making it effective for mood stabilization. Duloxetine (Cymbalta) (option A) is an SNRI used for depression and anxiety but is not indicated for acute mania or treatment-resistant bipolar disorder. Lithium (Eskalith) (option B) is a first-line mood stabilizer for bipolar disorder, but since this patient is treatment-resistant, lithium alone may not be effective. Selegiline (Emsam) (option D) is an MAOI antidepressant used for treatment-resistant depression but has no role in acute mania or bipolar disorder treatment. Thus, clozapine is the best choice for off-label use in treatment-resistant bipolar disorder, particularly when other medications have failed. A nurse practitioner (NP) is assessing a 25-year-old patient who has a history of a traumatic brain injury (TBI). Collateral information obtained by the patient's parents includes periods of agitation and aggression. The parents are concerned that one of the patient's medications may be causing the agitation. Which medications may cause paradoxical agitation given this patient's history? a. Antipsychotics b. Benzodiazepines c. Beta blockers d. Sedatives ANS: B Benzodiazepines may cause paradoxical agitation in patients with a history of traumatic brain injury (TBI). While benzodiazepines are typically used for sedation, anxiety, and agitation, they can have the opposite effect in some individuals, particularly in those with TBI, elderly patients, or individuals with cognitive impairments. This reaction may present as increased agitation, aggression, impulsivity, and disinhibition, worsening the patient's symptoms instead of alleviating them. Antipsychotics (option A) may be used for agitation, but they do not typically cause paradoxical agitation; however, some can have sedative effects or exacerbate cognitive impairment. Beta blockers (option C) are sometimes used off-label to reduce aggression and agitation in TBI patients. Sedatives (option D) is a broad category that includes benzodiazepines, but other sedatives, such as certain antipsychotics or alpha-2 agonists, do not typically cause paradoxical agitation. Thus, benzodiazepines are the most likely culprit for paradoxical agitation in this patient with a history of TBI. A nurse practitioner (NP) is evaluating a patient for shift work sleep disorder. The patient works from 11:00 p.m. to 7:00 a.m. five days per week and expresses having trouble staying asleep, feeling excessively fatigued, and often feeling restless. The patient denies previous history of these symptoms prior to starting the night shift. Which medication is FDA approved for this condition? a. Mirtazapine (Remeron) b. Trazodone (Desyrel) c. Modafinil (Provigil) d. Temazepam (Restoril) ANS: C Modafinil (Provigil) is FDA-approved for the treatment of shift work sleep disorder (SWSD). SWSD occurs in individuals who work nontraditional hours, such as night shifts, and experience excessive sleepiness during wake hours and difficulty sleeping during the day. Modafinil is a wake-promoting agent that helps improve alertness and reduce excessive daytime sleepiness without the addictive potential of traditional stimulants. Mirtazapine (Remeron) (option A) is an antidepressant with sedative properties, which may worsen sleep disturbances in SWSD rather than improve wakefulness. Trazodone (Desyrel) (option B) is commonly used for insomnia, but it is not FDA-approved for SWSD and may cause excessive sedation. Temazepam (Restoril) (option D) is a benzodiazepine hypnotic, which is used for insomnia but is not indicated for shift work sleep disorder. Thus, modafinil is the best choice for treating shift work sleep disorder to promote wakefulness and manage excessive fatigue. A patient with chronic nerve pain reports that they are experiencing restlessness, difficulty sleeping, ruminating thoughts, and constant worrying. Which drug should be prescribed to this patient to treat these symptoms? a. Gabapentin (Neurontin) b. Fluoxetine (Prozac) c. Venlafaxine (Effexor) d. Prazosin (Minipress) ANS: C Venlafaxine (Effexor) is the best choice for this patient, who presents with generalized anxiety disorder (GAD) symptoms alongside chronic nerve pain. Venlafaxine is a serotonin norepinephrine reuptake inhibitor (SNRI), which is effective in treating both anxiety disorders and neuropathic pain, making it the most appropriate treatment in this case. Gabapentin (Neurontin) (option A) is commonly used for nerve pain, but it does not directly address the patient's anxiety, ruminating thoughts, or difficulty sleeping. Fluoxetine (Prozac) (option B) is an SSRI, which is effective for anxiety but is less effective for chronic nerve pain compared to an SNRI like venlafaxine. Prazosin (Minipress) (option D) is used primarily for PTSD-related nightmares and hypertension, but it does not treat chronic nerve pain or generalized anxiety disorder. Thus, venlafaxine is the best choice to address both chronic nerve pain and anxiety symptoms in this patient. A nurse practitioner (NP) is interviewing a patient diagnosed with anxiety. The patient has been resistant to multiple FDA-approved psychotropic medications. Which off-label medication should this NP recommend first? a. Haloperidol (Haldol) b. Naltrexone (Revia) c. Quetiapine (Seroquel) d. Olanzapine (Zyprexa) ANS: C Quetiapine (Seroquel) is the best off-label medication to recommend first for treatment resistant anxiety. While not FDA-approved for generalized anxiety disorder (GAD), quetiapine has been shown to have anxiolytic effects due to its serotonin (5-HT2A) and dopamine (D2) receptor antagonism, along with histamine (H1) receptor blockade, which contributes to its sedative properties. Studies suggest it may be beneficial in patients who do not respond to standard first-line treatments such as SSRIs, SNRIs, or benzodiazepines. Haloperidol (Haldol) (option A) is a first-generation antipsychotic with high dopamine D2 blockade, which is not indicated for anxiety and may worsen symptoms due to its high extrapyramidal side effect risk. Naltrexone (Revia) (option B) is an opioid antagonist used for alcohol and opioid dependence but has no role in anxiety treatment. Olanzapine (Zyprexa) (option D) is an atypical antipsychotic, but it is generally not preferred for anxiety due to its higher risk of metabolic side effects compared to quetiapine. Thus, quetiapine is the best off-label option for treatment-resistant anxiety, especially when other first-line treatments have failed. A nurse practitioner (NP) is interviewing a patient who complains of insomnia. The patient has used many FDA-approved medications to treat the condition. The patient has no history of substance abuse or any other issues with medication compliance. Which off-label medication should the NP prescribe for this patient? a. Venlafaxine (Effexor) b. Amitriptyline (Elavil) c. Fluoxetine (Prozac) d. Bupropion (Wellbutrin) ANS: B Amitriptyline (Elavil) is the best off-label medication choice for this patient with treatment resistant insomnia. Amitriptyline is a tricyclic antidepressant (TCA) that has sedative properties due to its strong histamine (H1) receptor blockade, making it effective for sleep maintenance insomnia. It is often used at low doses for insomnia, chronic pain, and migraine prophylaxis. Venlafaxine (Effexor) (option A) is an SNRI that can actually cause insomnia as a side effect. Fluoxetine (Prozac) (option C) is an SSRI that is activating for many patients and may worsen insomnia. Bupropion (Wellbutrin) (option D) is a norepinephrine-dopamine reuptake inhibitor (NDRI) that is also stimulating and can contribute to sleep disturbances. Thus, amitriptyline is the best off-label choice for a patient with persistent insomnia who has not responded to FDA-approved treatments. A patient reports that they have had five years of heroin abuse but is currently sober. The patient was diagnosed with attention deficit hyperactivity disorder (ADHD) at 12 years of age and is currently struggling with focus and concentration. The patient was previously prescribed stimulant medications but prefers nonstimulants to support their sobriety. Which medication should be prescribed that has off-label use for this patient's condition? a. Amitriptyline (Elavil) b. Sertraline (Zoloft) c. Clonidine (Catapres) d. Prazosin (Minipress) ANS: C Clonidine (Catapres) is the best off-label medication choice for this patient with ADHD and a history of heroin abuse, who prefers nonstimulant treatment to support sobriety. Clonidine is an alpha-2 adrenergic agonist that helps regulate attention, reduce hyperactivity, and improve impulse control by modulating norepinephrine activity in the prefrontal cortex. It is FDA approved for pediatric ADHD but is also used off-label in adults who cannot tolerate or prefer to avoid stimulant medications. Amitriptyline (Elavil) (option A) is a tricyclic antidepressant used primarily for depression, insomnia, and chronic pain, but it is not a recognized treatment for ADHD. Sertraline (Zoloft) (option B) is an SSRI, effective for anxiety and depression but not for ADHD. Prazosin (Minipress) (option D) is an alpha-1 blocker used primarily for PTSD-related nightmares and hypertension, not ADHD. Thus, clonidine is the best choice for treating ADHD off-label in an adult patient with a history of substance use disorder, as it provides symptom relief without the risk of stimulant misuse. A patient is presently taking sertraline (Zoloft) for major depressive disorder with no reported benefit. The patient is reporting symptoms of fatigue that have not responded to the antidepressant. Which medication could be prescribed as an adjunct therapy for the fatigue based on current research? a. Mirtazapine (Remeron) b. Duloxetine (Cymbalta) c. Modafinil (Provigil) d. Atomoxetine (Strattera) ANS: C Modafinil (Provigil) is the best choice for adjunct therapy to address fatigue in a patient with major depressive disorder (MDD) who is not responding to sertraline (Zoloft). Modafinil is a wake-promoting agent that has been studied as an adjunct treatment for antidepressant resistant fatigue and excessive daytime sleepiness in patients with depression. It works by modulating dopamine and norepinephrine activity, improving alertness and cognitive function without the addictive potential of traditional stimulants. Mirtazapine (Remeron) (option A) is sedating and would likely worsen fatigue. Duloxetine (Cymbalta) (option B) is an SNRI, which may help with energy and motivation, but it is another antidepressant rather than a targeted adjunct for fatigue. Atomoxetine (Strattera) (option D) is a non-stimulant ADHD medication that affects norepinephrine, but it is not commonly used to treat fatigue in depression. Thus, modafinil is the best adjunct therapy for persistent fatigue in MDD that has not responded to sertraline. A nurse practitioner (NP) is working with a patient who is prescribed sertraline (Zoloft), hydroxyzine (Atarax), bupropion (Wellbutrin), and eszopiclone (Lunesta). The patient is complaining of a persistent bad taste in their mouth that has worsened over the past few days. Which medication is the cause of this side effect? a. Hydroxyzine (Atarax) b. Eszopiclone (Lunesta) c. Bupropion (Wellbutrin) d. Sertraline (Zoloft) ANS: B Eszopiclone (Lunesta) is the most likely cause of the persistent bad taste in this patient's mouth. A well-documented side effect of eszopiclone is dysgeusia (altered or bad taste), often described as metallic or bitter, which can persist even after waking. This is due to its effect on GABA receptors and how the drug is metabolized, leading to lingering taste disturbances. Hydroxyzine (Atarax) (option A) is an antihistamine that can cause dry mouth but is not commonly associated with altered taste. Bupropion (Wellbutrin) (option C) can cause dry mouth, but it is not a frequent cause of dysgeusia. Sertraline (Zoloft) (option D) can cause mild taste disturbances in some patients, but it is not as strongly associated with persistent bad taste as eszopiclone. Thus, eszopiclone is the most likely cause of this patient's persistent bad taste. A nurse practitioner (NP) is working with a patient who has major depressive disorder. Genetic testing identifies that medication that works on the serotonin reuptake transporter will not be effective for the patient. The NP must prescribe a medication that avoids this mechanism of action. Which medication should this NP prescribe? a. Fluvoxamine (Luvox) b. Escitalopram (Lexapro) c. Mirtazapine (Remeron) d. Sertraline (Zoloft) ANS: C Mirtazapine (Remeron) is the best choice because it does not work on the serotonin reuptake transporter (SERT). Instead of blocking serotonin reuptake, mirtazapine acts as a noradrenergic and specific serotonergic antidepressant (NaSSA) by blocking α2-adrenergic receptors, which increases the release of norepinephrine and serotonin, while also antagonizing 5-HT2 and 5 HT3 receptors. This mechanism makes it a good option for patients who do not respond to traditional selective serotonin reuptake inhibitors (SSRIs). Fluvoxamine (Luvox), Escitalopram (Lexapro), and Sertraline (Zoloft) (options A, B, and D) are all SSRIs, meaning they primarily act by inhibiting serotonin reuptake at the serotonin transporter (SERT), which the genetic testing indicates would not be effective for this patient. Thus, mirtazapine is the best choice for treating major depressive disorder without relying on the serotonin reuptake transporter. A nurse practitioner (NP) is interviewing a patient who is taking valproate (Depakote). The patient has been prescribed different medications for their bipolar disorder and is interested in why this medication is different. The patient is asking the NP how it works. Which action should the NP explain to this patient? a. It increases gamma-aminobutyric acid (GABA) concentrations by an unknown mechanism. b. It increases prefrontal cortex norepinephrine and dopamine neurotransmission. c. It inhibits neuronal activity in amygdala-centered fear circuits. d. It inhibits overall glutamatergic neurotransmission. ANS: A Valproate (Depakote) increases gamma-aminobutyric acid (GABA) concentrations by an unknown mechanism. GABA is the brain's primary inhibitory neurotransmitter, and increasing its levels helps stabilize mood, reduce neuronal excitability, and prevent mood swings in bipolar disorder. Although the exact mechanism is not fully understood, valproate is believed to enhance GABA synthesis and inhibit its degradation, leading to an overall increase in GABAergic activity, which has a calming effect on the brain. Increasing norepinephrine and dopamine in the prefrontal cortex (option B) is more characteristic of stimulants and certain antidepressants, not valproate. Inhibiting neuronal activity in amygdala-centered fear circuits (option C) is more relevant to anxiolytics like benzodiazepines or certain antidepressants. Inhibiting overall glutamatergic neurotransmission (option D) is a mechanism associated with NMDA receptor antagonists and mood stabilizers like lamotrigine, rather than valproate. Thus, valproate's primary mechanism involves increasing GABA concentrations, which contributes to its effectiveness in treating bipolar disorder. A patient is starting on bupropion (Wellbutrin) for major depressive disorder treatment. A nurse practitioner (NP) is providing education about how the medication works. What is the mechanism of action for this medication? a. Dopamine and norepinephrine reuptake blockade b. Acetylcholine and norepinephrine transmission blockade c. Monoamine oxidase and serotonin reuptake blockade d. Norepinephrine and serotonin transmission blockade ANS: A Bupropion (Wellbutrin) works by blocking the reuptake of dopamine and norepinephrine, making it a norepinephrine-dopamine reuptake inhibitor (NDRI). This mechanism increases dopamine and norepinephrine levels in the synapse, improving mood, energy, and motivation, which is particularly beneficial for major depressive disorder (MDD), especially in patients with fatigue, low motivation, and anhedonia. Acetylcholine and norepinephrine transmission blockade (option B) is not the mechanism of bupropion; however, bupropion is also a nicotinic acetylcholine receptor antagonist, which contributes to its use in smoking cessation. Monoamine oxidase and serotonin reuptake blockade (option C) describes monoamine oxidase inhibitors (MAOIs), such as phenelzine (Nardil), which inhibit the breakdown of multiple neurotransmitters. Norepinephrine and serotonin transmission blockade (option D) does not accurately describe bupropion's action, as it does not primarily target serotonin. Thus, bupropion's mechanism of action is dopamine and norepinephrine reuptake blockade, making it a unique antidepressant option for patients with MDD who may not respond well to SSRIs or SNRIs. A nurse practitioner (NP) is evaluating a new patient who has chronic diabetic neuropathy, generalized anxiety disorder, and recurrent moderate major depressive disorder. The patient wants to avoid polypharmacy. Which FDA-approved medication treats all three conditions? a. Bupropion (Wellbutrin) b. Duloxetine (Cymbalta) c. Desvenlafaxine (Pristiq) d. Venlafaxine (Effexor) ANS: B Duloxetine (Cymbalta) is FDA-approved to treat diabetic neuropathy, generalized anxiety disorder (GAD), and major depressive disorder (MDD), making it the best choice for this patient who wants to avoid polypharmacy. As a serotonin-norepinephrine reuptake inhibitor (SNRI), duloxetine enhances both serotonin and norepinephrine neurotransmission, providing antidepressant and anxiolytic effects, while also modulating pain perception in conditions like diabetic neuropathy. Bupropion (Wellbutrin) (option A) is not FDA-approved for anxiety or neuropathic pain, as it primarily targets dopamine and norepinephrine. Desvenlafaxine (Pristiq) (option C) and venlafaxine (Effexor) (option D) are SNRIs approved for MDD and GAD, but neither is FDA approved for diabetic neuropathy like duloxetine. Thus, duloxetine is the best choice because it effectively treats all three conditions with a single medication while minimizing polypharmacy. A patient is starting a selective serotonin reuptake inhibitor (SSRI)—paroxetine (Paxil)—for symptoms of depression. A nurse practitioner (NP) provides psychoeducation about common side effects of SSRIs. Which side effects should the NP discuss with this patient? a. Lightheadedness, orthostatic hypotension, and urine retention b. Low blood pressure, blurred vision, and appetite changes c. Appetite loss, increased energy, and increased blood pressure d. Trouble sleeping, nervousness, and sexual dysfucntion ANS: D The most common side effects of selective serotonin reuptake inhibitors (SSRIs), including paroxetine (Paxil), include trouble sleeping (insomnia), nervousness (anxiety, agitation), and sexual dysfunction (reduced libido, delayed orgasm, or anorgasmia). These side effects occur due to increased serotonin activity in the central nervous system, which can alter mood, arousal, and autonomic functions. Lightheadedness, orthostatic hypotension, and urine retention (option A) are more characteristic of tricyclic antidepressants (TCAs), which have anticholinergic and alpha adrenergic blocking effects. Low blood pressure, blurred vision, and appetite changes (option B) are not typical for SSRIs. Appetite loss, increased energy, and increased blood pressure (option C) are more associated with bupropion (Wellbutrin) or SNRIs like venlafaxine (Effexor), which can raise blood pressure. Thus, the most relevant side effects to discuss with a patient starting paroxetine are trouble sleeping, nervousness, and sexual dysfunction. A patient is starting atomoxetine (Strattera) for a new diagnosis of attention deficit hyperactivity disorder (ADHD). A nurse practitioner (NP) provides the patient with psychoeducation about common side effects of this medication. Which side effects should the NP discuss with this patient? a. Dizziness, slurred speech, tremor, and excessive thirst b. Increased energy, tremor, dry mouth, and agitation c. Weight gain, restlessness, drowsiness, and constipation d. Sedation, vomiting, nausea, and sexual dysfunction ANS: B Common side effects of atomoxetine (Strattera) include increased energy, tremor, dry mouth, and agitation. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) used for ADHD, and its effects on norepinephrine can lead to heightened alertness, restlessness, tremor, and dry mouth. Some patients may also experience insomnia, increased heart rate, and elevated blood pressure due to its stimulant-like properties. Dizziness, slurred speech, tremor, and excessive thirst (option A) are not typical of atomoxetine. Weight gain, restlessness, drowsiness, and constipation (option C) are more associated with antipsychotics or sedating antidepressants rather than atomoxetine. Sedation, vomiting, nausea, and sexual dysfunction (option D) can occur with some medications, but atomoxetine is more commonly associated with GI discomfort (nausea), irritability, and autonomic side effects rather than sedation or sexual dysfunction. Thus, the most relevant side effects to discuss with a patient starting atomoxetine are increased energy, tremor, dry mouth, and agitation. A nurse practitioner (NP) is working with a 58-year-old veteran who is experiencing major depression, post-traumatic stress disorder (PTSD), and a mild traumatic brain injury (mTBI) from a previous combat tour. The patient recently completed eye movement desensitization and reprocessing (EMDR) therapy and continues to struggle with symptoms of sadness, decreased motivation, lack of energy, and anhedonia. Currently, the patient is asking for a medication. Which medication is indicated for this patient? a. Duloxetine (Cymbalta) b. Fluvoxamine (Luvox) c. Mirtazapine (Remeron) d. Sertraline (Zoloft) ANS: D Sertraline (Zoloft) is the best choice for this patient, as it is FDA-approved for both major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). Sertraline is a selective serotonin reuptake inhibitor (SSRI) that effectively treats sadness, anhedonia, decreased motivation, and low energy, which are prominent symptoms in this patient. Given the patient's history of mild traumatic brain injury (mTBI), sertraline is also a well-tolerated option, as SSRIs are commonly used for mood disturbances following TBI. Duloxetine (Cymbalta) (option A) is an SNRI that is effective for depression and chronic pain but is not FDA-approved for PTSD. Fluvoxamine (Luvox) (option B) is an SSRI primarily used for obsessive-compulsive disorder (OCD), not PTSD or MDD. Mirtazapine (Remeron) (option C) is effective for depression, sleep disturbances, and appetite stimulation, but it is not first-line for PTSD and may cause excessive sedation, which could be problematic for a veteran with TBI. Thus, sertraline is the most appropriate medication, as it directly addresses both PTSD and major depressive disorder while being safe for a patient with mTBI. A nurse practitioner (NP) is working with an older adult patient who has dementia and is experiencing agitation and insomnia. What should this NP prescribe? a. 5 mg of zolpidem (Ambien) b. 2.5 mg of diazepam (Valium) c. 0.5 mg of clonazepam (Klonopin) d. 50 mg of trazodone (Desyrel) ANS: D Trazodone (Desyrel) 50 mg is the safest and most appropriate choice for an older adult with dementia experiencing agitation and insomnia. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that is commonly used off-label for sleep disturbances in elderly patients. It has sedating properties without significant risk of dependence or worsening cognitive impairment, making it a preferred option in this population. Zolpidem (Ambien) (option A), diazepam (Valium) (option B), and clonazepam (Klonopin) (option C) are all central nervous system (CNS) depressants that can increase the risk of falls, confusion, sedation, and paradoxical agitation in older adults with dementia. Benzodiazepines (diazepam and clonazepam), in particular, are not recommended due to their long half-life and potential to worsen cognitive impairment, increase fall risk, and cause dependency. Thus, trazodone 50 mg is the best choice for treating insomnia and agitation in an older adult with dementia, as it is safer and better tolerated than benzodiazepines or sedative-hypnotics. A nurse practitioner (NP) is working with a 17-year-old patient who is struggling with sleep onset insomnia. The patient recently traveled home to New York from the Philippines and has taken over-the-counter melatonin to help overcome the time change. It has been a week and the patient is still unable to adjust to the time change. Which medication is FDA indicated for this patient's condition? a. 7.5 mg of mirtazapine (Remeron) b. 50 mg of trazodone (Desyrel) c. 50 mg of quetiapine (Seroquel) d. 8 mg of ramelteon (Rozerem) ANS: D Ramelteon (Rozerem) 8 mg is the only FDA-approved medication for sleep-onset insomnia and is particularly useful for circadian rhythm disorders, such as jet lag. Ramelteon is a melatonin receptor agonist that selectively targets MT1 and MT2 receptors in the suprachiasmatic nucleus, which regulates the sleep-wake cycle. This mechanism helps reset the body's internal clock, making it the best choice for a teenager struggling to adjust to a time zone change. Mirtazapine (Remeron) (option A) and trazodone (Desyrel) (option B) are off-label sedating antidepressants that can promote sleep but are not FDA-indicated for sleep-onset insomnia or circadian rhythm adjustments. Quetiapine (Seroquel) (option C) is an atypical antipsychotic that is not FDA-approved for insomnia and has significant side effects, making it inappropriate for primary sleep concerns. Thus, ramelteon (Rozerem) is the best choice as it is FDA-approved for sleep-onset insomnia and works by adjusting circadian rhythms, which is particularly relevant for jet lag and time zone transitions. A 10-year-old patient presents with a history of autism spectrum disorder with agitation and physical aggression. The patient's weight is in the 99th percentile. Which medication should be prescribed for this patient? a. Haloperidol (Haldol) b. Aripiprazole (Abilify) c. Olanzapine (Zyprexa) d. Quetiapine (Seroquel) ANS: B Aripiprazole (Abilify) is the best choice because it is FDA-approved for irritability, agitation, and aggression in children with autism spectrum disorder (ASD). Aripiprazole is an atypical antipsychotic that works by modulating dopamine and serotonin receptors, helping to reduce aggression and agitation while minimizing sedation and metabolic side effects compared to other antipsychotics. Haloperidol (Haldol) (option A) is a first-generation antipsychotic that can reduce aggression but carries a higher risk of extrapyramidal side effects (EPS), such as tardive dyskinesia and dystonia, making it less favorable. Olanzapine (Zyprexa) (option C) and Quetiapine (Seroquel) (option D) are atypical antipsychotics but are not FDA-approved for autism-related agitation and have a higher risk of weight gain and metabolic complications, which is concerning given the child's weight being in the 99th percentile. Thus, aripiprazole (Abilify) is the best choice for managing agitation and aggression in a child with autism, given its FDA approval, effectiveness, and lower metabolic risk compared to other antipsychotics. A patient with a long history of schizophrenia is admitted to a mental health unit complaining of anxiety, restlessness, and auditory hallucinations that include commands to complete suicide by slamming their head on the floor until losing consciousness. The mental status exam indicates the patient has significant psychomotor agitation and is responding to internal stimuli. The patient's antipsychotic was changed six months ago from olanzapine (Zyprexa) 10 mg at bedtime to aripiprazole (Abilify) 20 mg daily. How should this patient's pharmacological treatment plan be managed to decrease the chances of suicide? a. Increase the dosage of aripiprazole (Abilify) b. Change the aripiprazole (Abilify) to clozapine (Clozaril) c. Change the aripiprazole (Abilify) to olanzapine (Zyprexa) d. Increase the aripiprazole (Abilify) and add propranolol (Inderal) ANS: B Changing aripiprazole (Abilify) to clozapine (Clozaril) is the best option for this patient, as clozapine is the only antipsychotic FDA-approved for reducing suicide risk in schizophrenia. The patient exhibits severe psychotic symptoms, psychomotor agitation, command auditory hallucinations, and an acute risk of self-harm, indicating treatment-resistant schizophrenia and inadequate symptom control on aripiprazole. Clozapine is particularly effective for patients with persistent suicidal ideation, aggression, or treatment-resistant psychosis. It has a unique mechanism that provides superior symptom control compared to other antipsychotics. Increasing the dose of aripiprazole (option A) is unlikely to be effective, as the patient has already been on 20 mg daily, which is within the typical therapeutic range. Switching back to olanzapine (option C) may help with symptoms, but it does not have the same suicide prevention benefits as clozapine. Adding propranolol (option D) may help with restlessness, but it does not address the persistent psychotic symptoms and suicidal ideation. Thus, clozapine is the best choice for this patient, given its FDA approval for suicide prevention in schizophrenia and its efficacy in treatment-resistant cases. A patient has been treated for depression with venlafaxine (Effexor) for approximately six months. Routine laboratory studies indicate the patient has developed hyponatremia. How should a nurse practitioner (NP) manage this patient's medication regimen? a. Discontinue venlafaxine and start mirtazapine (Remeron) b. Continue venlafaxine and add sodium chloride (Ocu-Disal) c. Continue venlafaxine and add mirtazapine (Remeron) d. Discontinue venlafaxine and start fluoxetine (Prozac) ANS: A Discontinue venlafaxine and start mirtazapine (Remeron). Venlafaxine (Effexor), like other serotonin-modulating antidepressants, can cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to hyponatremia. This condition is more common in elderly patients, those with medical comorbidities, and individuals sensitive to serotonin's effects on antidiuretic hormone (ADH) release. Given that the patient has already developed hyponatremia, discontinuing venlafaxine is necessary to prevent further complications such as severe electrolyte imbalance, confusion, or seizures. Mirtazapine (Remeron) is a good alternative, as it has a lower risk of hyponatremia compared to SSRIs and SNRIs. Mirtazapine also provides sedative properties, which may benefit patients with associated insomnia or appetite loss. Continuing venlafaxine and adding sodium chloride (option B) does not address the underlying cause (SIADH) and is not a preferred strategy. Adding mirtazapine to venlafaxine (option C) does not resolve the hyponatremia risk and may increase serotonin levels further, worsening the condition. Switching to fluoxetine (option D) is not ideal, as fluoxetine is also an SSRI with a similar risk of hyponatremia. A patient is experiencing full response to depression with escitalopram (Le